Home Drug IndexClinical Monograph

Arformoterol Uses, Dosage, Side Effects & Warnings | DrugsAtlas

Authoritative Clinical Reference

DRUG NAME: Arformoterol

Therapeutic Class: Bronchodilator

Subclass: Long-acting β2-adrenergic agonist (LABA)

Speciality: Pulmonology

Schedule (India): Schedule H

Route(s): Inhalation (nebulised)

Formulations Available in India:

Inhalation solution for nebulisation: 15 mcg/2 mL unit-dose vial (respule)

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

▶ Chronic Obstructive Pulmonary Disease (COPD) — Maintenance Treatment

Parameter	Recommendation
Starting dose	15 mcg via nebulisation twice daily (morning and evening)
Titration	Not applicable — fixed-dose regimen; use lowest effective dose
Usual maintenance dose	15 mcg twice daily
Maximum dose	30 mcg/day (administered as 15 mcg twice daily)

Clinical Notes:

NOT for acute bronchospasm or rescue therapy
Doses should be approximately 12 hours apart
Do not exceed recommended daily dose — risk of β2-agonist toxicity
Each unit-dose vial is for single use only; discard unused portion
Administer via standard jet nebuliser connected to air compressor

Important — Asthma Use:

NOT approved for asthma monotherapy
LABA monotherapy in asthma is associated with increased risk of asthma-related deaths
If considered for asthma, must always be used with concomitant inhaled corticosteroid (ICS)
Specialist pulmonologist supervision required
DPI combinations (ICS + LABA) preferred in asthma management

Secondary Indications — Adults Only (Off-label)

Not applicable. No established off-label indications in Indian practice.

PAEDIATRIC DOSING (Specialist Only)

Primary Indications (Approved / Standard in India)

▶ COPD in Adolescents ≥12 Years — SPECIALIST ONLY

Parameter	Recommendation
Starting dose	15 mcg via nebulisation twice daily
Titration	Not applicable
Usual maintenance dose	15 mcg twice daily
Maximum dose	30 mcg/day

Clinical Notes:

COPD is rare in adolescents; use only with confirmed diagnosis under pulmonologist care
Not recommended below 12 years of age due to lack of safety and efficacy data

Secondary Indications — Paediatrics (Off-label)

Indication	Details
Asthma (as adjunct to ICS) — OFF-LABEL	NOT RECOMMENDED in children; no strong Indian data for nebulised arformoterol in paediatric asthma. DPI-based ICS + LABA combinations preferred. Specialist pulmonologist decision only. Avoid unless no alternatives available.

Safety Monitoring (Paediatric):

Monitor for tremor, tachycardia, palpitations
Watch for paradoxical bronchospasm
Assess growth if on concurrent high-dose ICS
Periodic pulse and blood pressure monitoring

Age Restrictions:

NOT RECOMMENDED below 12 years of age except under specialist supervision with no alternative options

RENAL ADJUSTMENT

Renal Function	Recommendation
All stages of renal impairment	No dose adjustment required
Haemodialysis / Peritoneal dialysis	No specific data; systemic exposure is minimal with inhalation route

HEPATIC ADJUSTMENT

Severity	Recommendation
Mild impairment	No dose adjustment required
Moderate impairment	No dose adjustment required; monitor for adverse effects
Severe impairment	Use with caution — limited data available; monitor closely for systemic effects

CONTRAINDICATIONS

Known hypersensitivity to arformoterol, formoterol, or any component of the formulation
Primary treatment of acute bronchospasm or status asthmaticus (not a rescue medication)
Monotherapy in asthma without concurrent inhaled corticosteroid
Life-threatening deterioration of asthma

CAUTIONS

Cardiovascular disease (coronary artery disease, arrhythmias, hypertension) — risk of cardiovascular adverse effects
Hyperthyroidism — may exacerbate symptoms
Seizure disorders — β2-agonists may lower seizure threshold
Hypokalaemia — can further reduce serum potassium; risk increased with concurrent diuretics, steroids, or hypoxia
Diabetes mellitus — may cause transient hyperglycaemia
Pheochromocytoma (rare)
QT prolongation risk — caution in patients with baseline QT prolongation or on QT-prolonging drugs
Switching from another LABA — ensure appropriate washout; do not combine multiple LABAs
Paradoxical bronchospasm — discontinue immediately if occurs

PREGNANCY

Aspect	Details
Overall safety	Limited human data; use only if potential benefit justifies potential risk to fetus
When to use	Moderate-severe COPD uncontrolled with short-acting bronchodilators alone; specialist input recommended
Preferred alternatives	Salmeterol or budesonide/formoterol combinations (more pregnancy experience available)
Monitoring required	Maternal heart rate; uterine activity if used near term (β2-agonists may inhibit uterine contractions)

LACTATION

Aspect	Details
Compatibility	Likely compatible — minimal systemic absorption with inhalation route
Expected levels in milk	Low (systemic exposure is minimal)
Preferred alternatives	Salmeterol (more lactation data available)
Infant monitoring	Irritability, jitteriness, feeding difficulties, tachycardia

ELDERLY

Aspect	Recommendation
Starting dose	15 mcg twice daily (same as general adult population)
Titration	Not applicable; use lowest effective dose
Extra risks	Greater susceptibility to cardiovascular adverse effects (tachycardia, arrhythmias, hypertension); consider baseline ECG if cardiac history; monitor for hypokalaemia especially if on diuretics
Monitoring	Periodic ECG monitoring recommended in patients with cardiac comorbidities

MAJOR DRUG INTERACTIONS

Interacting Drug	Effect/Risk	Management
Non-selective β-blockers (propranolol, carvedilol)	Antagonise bronchodilator effect; may precipitate severe bronchospasm in COPD/asthma	Avoid combination; if β-blocker essential, use cardioselective agent (bisoprolol, metoprolol) with caution
MAO inhibitors	Potentiate cardiovascular effects of β2-agonists; risk of hypertensive crisis	Avoid within 14 days of MAO inhibitor use
Tricyclic antidepressants (amitriptyline, imipramine)	Potentiate cardiovascular effects; may prolong QT interval	Avoid combination or use with extreme caution; monitor ECG
Other LABAs (salmeterol, formoterol, indacaterol)	Additive β2-agonist toxicity; no additional benefit	Do not use concurrently; only one LABA at a time
Sympathomimetic agents (oral decongestants, adrenaline)	Additive cardiovascular effects	Avoid concurrent use or use with caution

MODERATE DRUG INTERACTIONS

Interacting Drug	Effect/Risk	Management
Non-potassium-sparing diuretics (furosemide, hydrochlorothiazide)	Additive hypokalaemia risk	Monitor serum potassium; supplement if needed
Corticosteroids (systemic)	May potentiate hypokalaemia with prolonged use	Monitor potassium levels with prolonged co-administration
Theophylline/aminophylline	Additive sympathomimetic effects (tachycardia, tremor, CNS stimulation)	Monitor heart rate and CNS symptoms; adjust doses if needed
Macrolide antibiotics (erythromycin, azithromycin, clarithromycin)	Potential QT prolongation	Monitor ECG in susceptible patients
Fluoroquinolones (levofloxacin, moxifloxacin)	Potential QT prolongation	Monitor ECG; avoid moxifloxacin if possible
Xanthine derivatives	Additive effects on heart rate and CNS	Monitor for adverse effects

COMMON ADVERSE EFFECTS

Tremor (fine tremor of hands)
Palpitations
Tachycardia
Headache
Muscle cramps
Nausea
Throat irritation or dryness
Dizziness
Nervousness

SERIOUS ADVERSE EFFECTS

Adverse Effect	Notes
Paradoxical bronchospasm	Requires immediate discontinuation; treat with short-acting bronchodilator
Severe hypokalaemia	Risk of cardiac arrhythmias; monitor electrolytes especially with concurrent diuretics
QT prolongation / Torsades de Pointes	Rare; monitor ECG in high-risk patients
Angina / Myocardial ischaemia	Discontinue if suspected; avoid in unstable cardiac disease
Severe hypertension	Monitor BP; reduce dose or discontinue if severe
Seizures	Rare; use with caution in epilepsy
Anaphylaxis / Severe hypersensitivity	Discontinue immediately; provide emergency treatment

MONITORING REQUIREMENTS

Timing	Parameters
Baseline	Spirometry (FEV1, FVC); ECG if cardiac history or risk factors; serum potassium if on diuretics or at risk of hypokalaemia; heart rate and blood pressure
After initiation (1–2 weeks)	Symptom control assessment; monitor for tremor, palpitations, tachycardia; check potassium if indicated
Long-term	Annual spirometry; periodic ECG in patients with cardiac comorbidities or on QT-prolonging drugs; serum electrolytes in at-risk populations; reassess need for continued LABA therapy

BRANDS AVAILABLE IN INDIA

Brovana Respules
Arforte Respules
Larbigen (15 mcg respules)
Arform (Cipla)
Aformes (Sun Pharma)

PRICE RANGE (INR)

Formulation	Price Range	Notes
15 mcg/2 mL unit-dose respule	₹20–₹35 per respule	Price varies by brand
Pack of 10 respules	₹180–₹300 per pack	Commonly dispensed pack size

Not under NLEM price control
Available in private retail pharmacies
Government supply availability varies by state

CLINICAL PEARLS

NOT a rescue medication — arformoterol has slow onset; always ensure patient has access to a short-acting bronchodilator (salbutamol nebulisation or MDI) for acute symptoms.
Never use LABA monotherapy in asthma — associated with increased asthma-related deaths; must always combine with ICS if used in asthma.
Nebuliser technique matters — ensure patients use a standard jet nebuliser with adequate flow rate (6–8 L/min); ultrasonic nebulisers not recommended.
Watch for hypokalaemia — especially relevant in patients on diuretics, systemic steroids, or during acute exacerbations with hypoxia; monitor potassium in at-risk patients.
One LABA only — do not combine with other long-acting β2-agonists (salmeterol, formoterol, indacaterol); no additional efficacy and increased toxicity risk.
Consider step-down — if patient achieves good symptom control for ≥3 months, reassess need for continued LABA or possibility of switching to ICS-LABA DPI combination if appropriate.

VERSION

RxIndia v0.9 — 28 February 2026

REFERENCES

CDSCO approved product information
Indian Pharmacopoeia
AIIMS Adult COPD Management Protocol
API Textbook of Medicine
Goodman & Gilman’s The Pharmacological Basis of Therapeutics (pharmacology reference)
GOLD Guidelines (supportive reference for COPD management)

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...

Arformoterol Uses, Dosage, Side Effects & Warnings | DrugsAtlas

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

Secondary Indications — Adults Only (Off-label)

PAEDIATRIC DOSING (Specialist Only)

Primary Indications (Approved / Standard in India)

Secondary Indications — Paediatrics (Off-label)

RENAL ADJUSTMENT

HEPATIC ADJUSTMENT

CONTRAINDICATIONS

CAUTIONS

PREGNANCY

LACTATION

ELDERLY

MAJOR DRUG INTERACTIONS

MODERATE DRUG INTERACTIONS

COMMON ADVERSE EFFECTS

SERIOUS ADVERSE EFFECTS

MONITORING REQUIREMENTS

BRANDS AVAILABLE IN INDIA

PRICE RANGE (INR)

CLINICAL PEARLS

TAGS

VERSION

REFERENCES

Clinical Responsibility

Is this information helpful?

RxIndia

Arformoterol Uses, Dosage, Side Effects & Warnings | DrugsAtlas

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

Secondary Indications — Adults Only (Off-label)

PAEDIATRIC DOSING (Specialist Only)

Primary Indications (Approved / Standard in India)

Secondary Indications — Paediatrics (Off-label)

RENAL ADJUSTMENT

HEPATIC ADJUSTMENT

CONTRAINDICATIONS

CAUTIONS

PREGNANCY

LACTATION

ELDERLY

MAJOR DRUG INTERACTIONS

MODERATE DRUG INTERACTIONS

COMMON ADVERSE EFFECTS

SERIOUS ADVERSE EFFECTS

MONITORING REQUIREMENTS

BRANDS AVAILABLE IN INDIA

PRICE RANGE (INR)

CLINICAL PEARLS

TAGS

VERSION

REFERENCES

Clinical Responsibility

Is this information helpful?